Microbiome Therapeutics MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy IndicationBy Route of AdministrationBy Source of MicrobiotaBy Development StageBy Therapeutic AreaBy Dosage FormBy Patient Age GroupBy Regulatory PathwayBy End UserBy Distribution Channel
Full title & scope — all 11 axes with their segments
Microbiome Therapeutics Market Size, Share & Industry Analysis, By Product Type (Live Biotherapeutic Products, Fecal Microbiota Products, Microbiome-Derived Small Molecules and Metabolites, Prebiotic-Based Therapeutics, Bacteriophage Therapeutics, Microbiome-Targeted Biologics and Antimicrobials), By Indication (Clostridioides difficile Infection, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Metabolic Disorders, Oncology and Immuno-Oncology, Dermatological Conditions, Neurological and CNS Disorders, Vaginal and Urogenital Infections, Other Indications), By Route of Administration (Oral, Rectal, Topical, Vaginal, Nasogastric/Nasoduodenal), By Source of Microbiota (Human Donor-Derived, Cultured Isolate-Derived, Synthetically Engineered, Food-Derived), By Development Stage (Approved and Marketed, Phase III, Phase II, Phase I, Preclinical), By Therapeutic Area (Gastroenterology, Infectious Diseases, Metabolic and Endocrine, Oncology, Dermatology, Neurology, Women's Health), By Dosage Form (Capsules, Liquid Suspensions, Powders, Topical Formulations, Tablets), By Patient Age Group (Adults, Geriatric, Paediatric), By Regulatory Pathway (Biologic (BLA/Drug) Pathway, Medicinal Product (EMA/MAA) Pathway, Enforcement Discretion/Special Access, Hospital Exemption), By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, Homecare Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies), and Regional Forecast, 2026-2034
Last Updated: Nov 2, 2026Format: PDFReport ID: CDI-248828
TOC
Full table of contents for the published report, chapter by chapter.
Full chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
1.1Strategic Imperatives
1.2Definition
1.3Microbiome Therapeutics Comparison By Segments
Chapter 2.Premium Insights
2.1Top 3 Trends to Watch
2.2Top 3 Strategies Followed by Major Players
2.3Top 3 Predictions by Contrive Datum Insights
2.4Top Investment Pockets
2.4.1Market Attractiveness Analysis, By Product Type
2.4.2Market Attractiveness Analysis, By Indication
2.4.3Market Attractiveness Analysis, By Route of Administration
2.4.4Market Attractiveness Analysis, By Source of Microbiota
2.4.5Market Attractiveness Analysis, By Development Stage
2.4.6Market Attractiveness Analysis, By Therapeutic Area
2.4.7Market Attractiveness Analysis, By Dosage Form
2.4.8Market Attractiveness Analysis, By Patient Age Group
2.4.9Market Attractiveness Analysis, By Regulatory Pathway
2.4.10Market Attractiveness Analysis, By End User
2.4.11Market Attractiveness Analysis, By Distribution Channel
2.5Key Market Participants — Intensity Mapping
2.6Insights From Primary Respondents
Chapter 3.Market Definition
Chapter 4.Research Methodology
4.1Research Approach
4.1.1Research Programs / Design
4.1.2Market Size Estimation
4.2Data Sources
4.2.1Secondary Sources
4.2.1.1Preliminary Data Mining
4.2.2Primary Sources
4.2.2.1Statistical Model
4.2.2.2Data Triangulation
4.2.2.3Research Objective
4.3Flow Of Methodology
4.4Top-Down / Bottom-Up Approach
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
6.1Market Focus & Value Proposition
6.1.1Target Customers, Priority Markets, and Core Value Proposition
6.1.2Product Differentiation and Positioning Logic
6.2Commercial Model & Pricing Strategy
6.2.1Pricing Approach and Value Capture
6.2.2Contracting, Bundling, and Monetization Framework
6.3Channels, Sales & Partnerships
6.3.1Direct and Indirect Channel Strategy
6.3.2Sales Execution Model and Strategic Partnerships
6.4Marketing, Launch & Execution Roadmap
6.4.1Marketing and Demand Generation Approach
6.4.2Launch Sequencing and Rollout Plan
6.5Operational Readiness & Governance KPIs
6.5.1Supply Chain and Operational Preparedness
6.5.2Regulatory Considerations, Risks, and Performance Tracking
Chapter 7.Market Trends, Strategy & Dynamics
7.1Trends Overview
7.2Strategic Overview
7.3Market Drivers
7.4Market Restraints
7.5Market Opportunities
7.6Market Challenges
7.7Impact Analysis of Market Dynamics
Chapter 8.Porter's Five Forces
8.1Bargaining Power of Suppliers
8.2Bargaining Power of Buyers
8.3Threat of New Entrants
8.4Threat of Substitutes
8.5Competitive Rivalry
Chapter 9.PESTEL Analysis
9.1Political
9.2Economic
9.3Social
9.4Technological
9.5Environmental
9.6Legal
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
12.1Macro-Economic Factors Overview
12.2Forecast Factors — Relevance and Impact
Chapter 13.Market Cost Analysis
13.1Key Raw Materials Analysis
13.1.1Key Raw Materials
13.1.2Price Trend of Key Raw Materials
13.1.3Key Suppliers of Raw Materials
13.1.4Market Concentration Rate of Raw Materials
13.1.5Raw Materials
13.1.6Labor Cost
Chapter 14.Market Supply-Side Analysis
14.1Raw Materials
14.2Price Trends
14.3Industry Chain
14.4Raw Materials Sourcing
14.5Raw Materials Sources of Major Manufacturers
14.6Downstream Buyers
Chapter 15.Global Microbiome Therapeutics Market Size & Projections, 2020–2034, Revenue (USD Million)
15.1Global Microbiome Therapeutics Market Size — Total
15.2Market Size, by Segment (By Product Type, By Indication, By Route of Administration, By Source of Microbiota, By Development Stage, By Therapeutic Area, By Dosage Form, By Patient Age Group, By Regulatory Pathway, By End User, By Distribution Channel)
Chapter 16.Global Microbiome Therapeutics Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
16.1Introduction
16.2Global Microbiome Therapeutics Market Size, By Product Type, 2020–2034, Revenue (USD Million)
16.3Global Microbiome Therapeutics Market Share, By Product Type (%)
16.3.1Live Biotherapeutic Products (LBPs)
16.3.1.1Market Size, By Live Biotherapeutic Products (LBPs), 2020–2034, Revenue (USD Million)
16.3.1.2Live Biotherapeutic Products (LBPs) Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
16.3.1.3Live Biotherapeutic Products (LBPs) Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
16.3.1.4Live Biotherapeutic Products (LBPs) Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
16.3.1.5Live Biotherapeutic Products (LBPs) Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
16.3.1.6Live Biotherapeutic Products (LBPs) Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
16.3.1.7Live Biotherapeutic Products (LBPs) Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
16.3.1.8Live Biotherapeutic Products (LBPs) Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
16.3.1.9Live Biotherapeutic Products (LBPs) Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
16.3.1.10Live Biotherapeutic Products (LBPs) Size and Projections, By End User, 2020–2034, Revenue (USD Million)
16.3.1.11Live Biotherapeutic Products (LBPs) Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
16.3.2Fecal Microbiota Products
16.3.3Microbiome-Derived Small Molecules and Metabolites
16.3.4Prebiotic-Based Therapeutics
16.3.5Bacteriophage Therapeutics
16.3.6Microbiome-Targeted Biologics and Antimicrobials
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 16.3.1 (Live Biotherapeutic Products (LBPs)).
Chapter 17.Global Microbiome Therapeutics Market Overview, By Indication, 2020–2034, Revenue (USD Million)
17.1Introduction
17.2Global Microbiome Therapeutics Market Size, By Indication, 2020–2034, Revenue (USD Million)
17.3Global Microbiome Therapeutics Market Share, By Indication (%)
17.3.1Clostridioides difficile Infection
17.3.1.1Market Size, By Clostridioides difficile Infection, 2020–2034, Revenue (USD Million)
17.3.1.2Clostridioides difficile Infection Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
17.3.1.3Clostridioides difficile Infection Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
17.3.1.4Clostridioides difficile Infection Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
17.3.1.5Clostridioides difficile Infection Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
17.3.1.6Clostridioides difficile Infection Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
17.3.1.7Clostridioides difficile Infection Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
17.3.1.8Clostridioides difficile Infection Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
17.3.1.9Clostridioides difficile Infection Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
17.3.1.10Clostridioides difficile Infection Size and Projections, By End User, 2020–2034, Revenue (USD Million)
17.3.1.11Clostridioides difficile Infection Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
17.3.2Inflammatory Bowel Disease
17.3.3Irritable Bowel Syndrome
17.3.4Metabolic Disorders
17.3.5Oncology and Immuno-Oncology
17.3.6Dermatological Conditions
17.3.7Neurological and CNS Disorders
17.3.8Vaginal and Urogenital Infections
17.3.9Other Indications
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 17.3.1 (Clostridioides difficile Infection).
Chapter 18.Global Microbiome Therapeutics Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
18.1Introduction
18.2Global Microbiome Therapeutics Market Size, By Route of Administration, 2020–2034, Revenue (USD Million)
18.3Global Microbiome Therapeutics Market Share, By Route of Administration (%)
18.3.1Oral
18.3.1.1Market Size, By Oral, 2020–2034, Revenue (USD Million)
18.3.1.2Oral Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
18.3.1.3Oral Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
18.3.1.4Oral Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
18.3.1.5Oral Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
18.3.1.6Oral Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
18.3.1.7Oral Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
18.3.1.8Oral Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
18.3.1.9Oral Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
18.3.1.10Oral Size and Projections, By End User, 2020–2034, Revenue (USD Million)
18.3.1.11Oral Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
18.3.2Rectal
18.3.3Topical
18.3.4Vaginal
18.3.5Nasogastric/Nasoduodenal
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 18.3.1 (Oral).
Chapter 19.Global Microbiome Therapeutics Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
19.1Introduction
19.2Global Microbiome Therapeutics Market Size, By Source of Microbiota, 2020–2034, Revenue (USD Million)
19.3Global Microbiome Therapeutics Market Share, By Source of Microbiota (%)
19.3.1Human Donor-Derived
19.3.1.1Market Size, By Human Donor-Derived, 2020–2034, Revenue (USD Million)
19.3.1.2Human Donor-Derived Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
19.3.1.3Human Donor-Derived Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
19.3.1.4Human Donor-Derived Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
19.3.1.5Human Donor-Derived Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
19.3.1.6Human Donor-Derived Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
19.3.1.7Human Donor-Derived Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
19.3.1.8Human Donor-Derived Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
19.3.1.9Human Donor-Derived Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
19.3.1.10Human Donor-Derived Size and Projections, By End User, 2020–2034, Revenue (USD Million)
19.3.1.11Human Donor-Derived Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
19.3.2Cultured Isolate-Derived
19.3.3Synthetically Engineered
19.3.4Food-Derived
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 19.3.1 (Human Donor-Derived).
Chapter 20.Global Microbiome Therapeutics Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
20.1Introduction
20.2Global Microbiome Therapeutics Market Size, By Development Stage, 2020–2034, Revenue (USD Million)
20.3Global Microbiome Therapeutics Market Share, By Development Stage (%)
20.3.1Approved and Marketed
20.3.1.1Market Size, By Approved and Marketed, 2020–2034, Revenue (USD Million)
20.3.1.2Approved and Marketed Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
20.3.1.3Approved and Marketed Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
20.3.1.4Approved and Marketed Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
20.3.1.5Approved and Marketed Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
20.3.1.6Approved and Marketed Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
20.3.1.7Approved and Marketed Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
20.3.1.8Approved and Marketed Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
20.3.1.9Approved and Marketed Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
20.3.1.10Approved and Marketed Size and Projections, By End User, 2020–2034, Revenue (USD Million)
20.3.1.11Approved and Marketed Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
20.3.2Phase III
20.3.3Phase II
20.3.4Phase I
20.3.5Preclinical
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 20.3.1 (Approved and Marketed).
Chapter 21.Global Microbiome Therapeutics Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
21.1Introduction
21.2Global Microbiome Therapeutics Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Million)
21.3Global Microbiome Therapeutics Market Share, By Therapeutic Area (%)
21.3.1Gastroenterology
21.3.1.1Market Size, By Gastroenterology, 2020–2034, Revenue (USD Million)
21.3.1.2Gastroenterology Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
21.3.1.3Gastroenterology Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
21.3.1.4Gastroenterology Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
21.3.1.5Gastroenterology Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
21.3.1.6Gastroenterology Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
21.3.1.7Gastroenterology Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
21.3.1.8Gastroenterology Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
21.3.1.9Gastroenterology Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
21.3.1.10Gastroenterology Size and Projections, By End User, 2020–2034, Revenue (USD Million)
21.3.1.11Gastroenterology Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
21.3.2Infectious Diseases
21.3.3Metabolic and Endocrine
21.3.4Oncology
21.3.5Dermatology
21.3.6Neurology
21.3.7Women's Health
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 21.3.1 (Gastroenterology).
Chapter 22.Global Microbiome Therapeutics Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
22.1Introduction
22.2Global Microbiome Therapeutics Market Size, By Dosage Form, 2020–2034, Revenue (USD Million)
22.3Global Microbiome Therapeutics Market Share, By Dosage Form (%)
22.3.1Capsules
22.3.1.1Market Size, By Capsules, 2020–2034, Revenue (USD Million)
22.3.1.2Capsules Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
22.3.1.3Capsules Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
22.3.1.4Capsules Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
22.3.1.5Capsules Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
22.3.1.6Capsules Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
22.3.1.7Capsules Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
22.3.1.8Capsules Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
22.3.1.9Capsules Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
22.3.1.10Capsules Size and Projections, By End User, 2020–2034, Revenue (USD Million)
22.3.1.11Capsules Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
22.3.2Liquid Suspensions
22.3.3Powders
22.3.4Topical Formulations
22.3.5Tablets
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 22.3.1 (Capsules).
Chapter 23.Global Microbiome Therapeutics Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
23.1Introduction
23.2Global Microbiome Therapeutics Market Size, By Patient Age Group, 2020–2034, Revenue (USD Million)
23.3Global Microbiome Therapeutics Market Share, By Patient Age Group (%)
23.3.1Adults
23.3.1.1Market Size, By Adults, 2020–2034, Revenue (USD Million)
23.3.1.2Adults Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
23.3.1.3Adults Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
23.3.1.4Adults Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
23.3.1.5Adults Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
23.3.1.6Adults Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
23.3.1.7Adults Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
23.3.1.8Adults Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
23.3.1.9Adults Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
23.3.1.10Adults Size and Projections, By End User, 2020–2034, Revenue (USD Million)
23.3.1.11Adults Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
23.3.2Geriatric
23.3.3Paediatric
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 23.3.1 (Adults).
Chapter 24.Global Microbiome Therapeutics Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
24.1Introduction
24.2Global Microbiome Therapeutics Market Size, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
24.3Global Microbiome Therapeutics Market Share, By Regulatory Pathway (%)
24.3.1Biologic (BLA/Drug) Pathway
24.3.1.1Market Size, By Biologic (BLA/Drug) Pathway, 2020–2034, Revenue (USD Million)
24.3.1.2Biologic (BLA/Drug) Pathway Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
24.3.1.3Biologic (BLA/Drug) Pathway Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
24.3.1.4Biologic (BLA/Drug) Pathway Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
24.3.1.5Biologic (BLA/Drug) Pathway Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
24.3.1.6Biologic (BLA/Drug) Pathway Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
24.3.1.7Biologic (BLA/Drug) Pathway Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
24.3.1.8Biologic (BLA/Drug) Pathway Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
24.3.1.9Biologic (BLA/Drug) Pathway Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
24.3.1.10Biologic (BLA/Drug) Pathway Size and Projections, By End User, 2020–2034, Revenue (USD Million)
24.3.1.11Biologic (BLA/Drug) Pathway Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
24.3.2Medicinal Product (EMA/MAA) Pathway
24.3.3Enforcement Discretion/Special Access
24.3.4Hospital Exemption
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 24.3.1 (Biologic (BLA/Drug) Pathway).
Chapter 25.Global Microbiome Therapeutics Market Overview, By End User, 2020–2034, Revenue (USD Million)
25.1Introduction
25.2Global Microbiome Therapeutics Market Size, By End User, 2020–2034, Revenue (USD Million)
25.3Global Microbiome Therapeutics Market Share, By End User (%)
25.3.1Hospitals
25.3.1.1Market Size, By Hospitals, 2020–2034, Revenue (USD Million)
25.3.1.2Hospitals Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
25.3.1.3Hospitals Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
25.3.1.4Hospitals Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
25.3.1.5Hospitals Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
25.3.1.6Hospitals Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
25.3.1.7Hospitals Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
25.3.1.8Hospitals Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
25.3.1.9Hospitals Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
25.3.1.10Hospitals Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
25.3.1.11Hospitals Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
25.3.2Specialty Clinics
25.3.3Ambulatory Care Centers
25.3.4Homecare Settings
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 25.3.1 (Hospitals).
Chapter 26.Global Microbiome Therapeutics Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
26.1Introduction
26.2Global Microbiome Therapeutics Market Size, By Distribution Channel, 2020–2034, Revenue (USD Million)
26.3Global Microbiome Therapeutics Market Share, By Distribution Channel (%)
26.3.1Hospital Pharmacies
26.3.1.1Market Size, By Hospital Pharmacies, 2020–2034, Revenue (USD Million)
26.3.1.2Hospital Pharmacies Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
26.3.1.3Hospital Pharmacies Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
26.3.1.4Hospital Pharmacies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
26.3.1.5Hospital Pharmacies Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
26.3.1.6Hospital Pharmacies Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
26.3.1.7Hospital Pharmacies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
26.3.1.8Hospital Pharmacies Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
26.3.1.9Hospital Pharmacies Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
26.3.1.10Hospital Pharmacies Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
26.3.1.11Hospital Pharmacies Size and Projections, By End User, 2020–2034, Revenue (USD Million)
26.3.2Retail Pharmacies
26.3.3Specialty Pharmacies
26.3.4Online Pharmacies
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 26.3.1 (Hospital Pharmacies).
Chapter 27.Global Microbiome Therapeutics Market Size — Segment Comparison
Chapter 28.Global Microbiome Therapeutics Geography Overview, 2020–2034, Revenue (USD Million)
28.1Revenue, By Geography, 2020–2034, Revenue (USD Million)
28.2Share, By Geography, 2020–2034 (%)
28.3Share, By Geography Analysis, 2025, Market Share and CAGR
28.4Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Chapter 29.North America Microbiome Therapeutics Market Deep-Dive, 2020–2034, Revenue (USD Million)
29.1Overview, 2020–2034
29.2Size and Projections, 2020–2034, Revenue (USD Million)
29.2.1By Product Type, 2020–2034
29.2.2By Indication, 2020–2034
29.2.3By Route of Administration, 2020–2034
29.2.4By Source of Microbiota, 2020–2034
29.2.5By Development Stage, 2020–2034
29.2.6By Therapeutic Area, 2020–2034
29.2.7By Dosage Form, 2020–2034
29.2.8By Patient Age Group, 2020–2034
29.2.9By Regulatory Pathway, 2020–2034
29.2.10By End User, 2020–2034
29.2.11By Distribution Channel, 2020–2034
29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
29.3.1US
29.3.1.1US — Key Country Dynamics
29.3.1.2US — Regulatory Framework
29.3.1.3US — Competitive Scenario
29.3.1.4US — Market Overview, 2020–2034, Revenue (USD Million)
29.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Million)
29.3.1.6US Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
29.3.1.7US Market Overview, By Indication, 2020–2034, Revenue (USD Million)
29.3.1.8US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
29.3.1.9US Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
29.3.1.10US Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
29.3.1.11US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
29.3.1.12US Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
29.3.1.13US Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
29.3.1.14US Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
29.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Million)
29.3.1.16US Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
29.3.2Canada
29.3.3Mexico
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 29.3.1 (US).
Chapter 30.Europe Microbiome Therapeutics Market Deep-Dive, 2020–2034, Revenue (USD Million)
30.1Overview, 2020–2034
30.2Size and Projections, 2020–2034, Revenue (USD Million)
30.2.1By Product Type, 2020–2034
30.2.2By Indication, 2020–2034
30.2.3By Route of Administration, 2020–2034
30.2.4By Source of Microbiota, 2020–2034
30.2.5By Development Stage, 2020–2034
30.2.6By Therapeutic Area, 2020–2034
30.2.7By Dosage Form, 2020–2034
30.2.8By Patient Age Group, 2020–2034
30.2.9By Regulatory Pathway, 2020–2034
30.2.10By End User, 2020–2034
30.2.11By Distribution Channel, 2020–2034
30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
30.3.1Germany
30.3.1.1Germany — Key Country Dynamics
30.3.1.2Germany — Regulatory Framework
30.3.1.3Germany — Competitive Scenario
30.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Million)
30.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Million)
30.3.1.6Germany Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
30.3.1.7Germany Market Overview, By Indication, 2020–2034, Revenue (USD Million)
30.3.1.8Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
30.3.1.9Germany Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
30.3.1.10Germany Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
30.3.1.11Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
30.3.1.12Germany Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
30.3.1.13Germany Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
30.3.1.14Germany Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
30.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Million)
30.3.1.16Germany Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
30.3.2France
30.3.3Italy
30.3.4Spain
30.3.5UK
30.3.6Nordic Countries
30.3.7Benelux Union
30.3.8Rest of Europe
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 30.3.1 (Germany).
Chapter 31.Asia Pacific Microbiome Therapeutics Market Deep-Dive, 2020–2034, Revenue (USD Million)
31.1Overview, 2020–2034
31.2Size and Projections, 2020–2034, Revenue (USD Million)
31.2.1By Product Type, 2020–2034
31.2.2By Indication, 2020–2034
31.2.3By Route of Administration, 2020–2034
31.2.4By Source of Microbiota, 2020–2034
31.2.5By Development Stage, 2020–2034
31.2.6By Therapeutic Area, 2020–2034
31.2.7By Dosage Form, 2020–2034
31.2.8By Patient Age Group, 2020–2034
31.2.9By Regulatory Pathway, 2020–2034
31.2.10By End User, 2020–2034
31.2.11By Distribution Channel, 2020–2034
31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
31.3.1India
31.3.1.1India — Key Country Dynamics
31.3.1.2India — Regulatory Framework
31.3.1.3India — Competitive Scenario
31.3.1.4India — Market Overview, 2020–2034, Revenue (USD Million)
31.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Million)
31.3.1.6India Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
31.3.1.7India Market Overview, By Indication, 2020–2034, Revenue (USD Million)
31.3.1.8India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
31.3.1.9India Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
31.3.1.10India Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
31.3.1.11India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
31.3.1.12India Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
31.3.1.13India Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
31.3.1.14India Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
31.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Million)
31.3.1.16India Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
31.3.2Australia
31.3.3China
31.3.4China (Taiwan)
31.3.5Japan
31.3.6South Korea
31.3.7Southeast Asia
31.3.8Indonesia
31.3.9Thailand
31.3.10Malaysia
31.3.11Singapore
31.3.12Rest of Asia Pacific
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 31.3.1 (India).
Chapter 32.Latin America Microbiome Therapeutics Market Deep-Dive, 2020–2034, Revenue (USD Million)
32.1Overview, 2020–2034
32.2Size and Projections, 2020–2034, Revenue (USD Million)
32.2.1By Product Type, 2020–2034
32.2.2By Indication, 2020–2034
32.2.3By Route of Administration, 2020–2034
32.2.4By Source of Microbiota, 2020–2034
32.2.5By Development Stage, 2020–2034
32.2.6By Therapeutic Area, 2020–2034
32.2.7By Dosage Form, 2020–2034
32.2.8By Patient Age Group, 2020–2034
32.2.9By Regulatory Pathway, 2020–2034
32.2.10By End User, 2020–2034
32.2.11By Distribution Channel, 2020–2034
32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
32.3.1Brazil
32.3.1.1Brazil — Key Country Dynamics
32.3.1.2Brazil — Regulatory Framework
32.3.1.3Brazil — Competitive Scenario
32.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Million)
32.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Million)
32.3.1.6Brazil Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
32.3.1.7Brazil Market Overview, By Indication, 2020–2034, Revenue (USD Million)
32.3.1.8Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
32.3.1.9Brazil Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
32.3.1.10Brazil Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
32.3.1.11Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
32.3.1.12Brazil Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
32.3.1.13Brazil Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
32.3.1.14Brazil Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
32.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Million)
32.3.1.16Brazil Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
32.3.2Argentina
32.3.3Rest of Latin America
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 32.3.1 (Brazil).
Chapter 33.Middle East and Africa Microbiome Therapeutics Market Deep-Dive, 2020–2034, Revenue (USD Million)
33.1Overview, 2020–2034
33.2Size and Projections, 2020–2034, Revenue (USD Million)
33.2.1By Product Type, 2020–2034
33.2.2By Indication, 2020–2034
33.2.3By Route of Administration, 2020–2034
33.2.4By Source of Microbiota, 2020–2034
33.2.5By Development Stage, 2020–2034
33.2.6By Therapeutic Area, 2020–2034
33.2.7By Dosage Form, 2020–2034
33.2.8By Patient Age Group, 2020–2034
33.2.9By Regulatory Pathway, 2020–2034
33.2.10By End User, 2020–2034
33.2.11By Distribution Channel, 2020–2034
33.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
33.3.1GCC
33.3.1.1GCC — Key Country Dynamics
33.3.1.2GCC — Regulatory Framework
33.3.1.3GCC — Competitive Scenario
33.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Million)
33.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Million)
33.3.1.6GCC Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
33.3.1.7GCC Market Overview, By Indication, 2020–2034, Revenue (USD Million)
33.3.1.8GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
33.3.1.9GCC Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
33.3.1.10GCC Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
33.3.1.11GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
33.3.1.12GCC Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
33.3.1.13GCC Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
33.3.1.14GCC Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
33.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Million)
33.3.1.16GCC Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
33.3.2Egypt
33.3.3South Africa
33.3.4Rest of the Middle East & Africa
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 33.3.1 (GCC).
Chapter 34.Application / Use-Case Analysis
Chapter 35.Vendor Capability Scorecard
Chapter 36.Scenario Forecasts
36.1Bull-case Trajectory
36.2Base-case Trajectory
36.3Bear-case Trajectory
Chapter 37.Top 10 Key Clients of Top 10 Players
Chapter 38.Top 10 Suppliers
Chapter 39.Competitive Landscape
39.1Ferring Pharmaceuticals
39.2Seres Therapeutics, Inc.
39.3Nestlé Health Science
39.4Vedanta Biosciences, Inc.
39.5MaaT Pharma SA
39.6Finch Therapeutics Group, Inc.
39.7Microbiotica Ltd
39.8Destiny Pharma plc
39.94D Pharma plc
39.10Evelo Biosciences, Inc.
39.11Kaleido Biosciences, Inc.
39.12AOBiome Therapeutics, Inc.
39.13Osel, Inc.
39.14Rebiotix Inc.
39.15Assembly Biosciences, Inc.
39.16Enterome SA
39.17Genome & Company
39.18Siolta Therapeutics, Inc.
39.19Exeliom Biosciences
39.20NuBiyota
39.21Biomica Ltd
39.22Servatus Ltd
39.23Taisho Pharmaceutical Co., Ltd.
39.24Sanofi S.A.
39.25Danone S.A.
39.26Sun Pharmaceutical Industries Ltd.
39.27Genetic Analysis AS
39.28Federation Bio
Chapter 40.Partnerships & M&A
Chapter 41.Key Vendor Analysis
41.1Ferring Pharmaceuticals
41.2Seres Therapeutics, Inc.
41.3Nestlé Health Science
41.4Vedanta Biosciences, Inc.
41.5MaaT Pharma SA
41.6Finch Therapeutics Group, Inc.
41.7Microbiotica Ltd
41.8Destiny Pharma plc
41.94D Pharma plc
41.10Evelo Biosciences, Inc.
41.11Kaleido Biosciences, Inc.
41.12AOBiome Therapeutics, Inc.
41.13Osel, Inc.
41.14Rebiotix Inc.
41.15Assembly Biosciences, Inc.
41.16Enterome SA
41.17Genome & Company
41.18Siolta Therapeutics, Inc.
41.19Exeliom Biosciences
41.20NuBiyota
41.21Biomica Ltd
41.22Servatus Ltd
41.23Taisho Pharmaceutical Co., Ltd.
41.24Sanofi S.A.
41.25Danone S.A.
41.26Sun Pharmaceutical Industries Ltd.
41.27Genetic Analysis AS
41.28Federation Bio
Chapter 42.Marketing Strategy Analysis, Distributors & Traders
Chapter 43.Outlook of the Market
Chapter 44.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
Figure 2.1Top 3 Trends to Watch
Figure 2.4Top Investment Pockets
Figure 2.4.1Market Attractiveness Analysis, By Product Type
Figure 2.4.2Market Attractiveness Analysis, By Indication
Figure 2.4.3Market Attractiveness Analysis, By Route of Administration
Figure 2.4.4Market Attractiveness Analysis, By Source of Microbiota
Figure 2.4.5Market Attractiveness Analysis, By Development Stage
Figure 2.4.6Market Attractiveness Analysis, By Therapeutic Area
Figure 2.4.7Market Attractiveness Analysis, By Dosage Form
Figure 2.4.8Market Attractiveness Analysis, By Patient Age Group
Figure 2.4.9Market Attractiveness Analysis, By Regulatory Pathway
Figure 2.4.10Market Attractiveness Analysis, By End User
Figure 2.4.11Market Attractiveness Analysis, By Distribution Channel
Figure 2.5Key Market Participants — Intensity Mapping
Figure 4.2.2.2Data Triangulation
Figure 4.3Flow Of Methodology
Figure 4.4Top-Down / Bottom-Up Approach
Figure 6.1.2Product Differentiation and Positioning Logic
Figure 16.3Global Microbiome Therapeutics Market Share, By Product Type (%)
Figure 17.3Global Microbiome Therapeutics Market Share, By Indication (%)
Figure 18.3Global Microbiome Therapeutics Market Share, By Route of Administration (%)
Figure 19.3Global Microbiome Therapeutics Market Share, By Source of Microbiota (%)
Figure 20.3Global Microbiome Therapeutics Market Share, By Development Stage (%)
Figure 21.3Global Microbiome Therapeutics Market Share, By Therapeutic Area (%)
Figure 22.3Global Microbiome Therapeutics Market Share, By Dosage Form (%)
Figure 23.3Global Microbiome Therapeutics Market Share, By Patient Age Group (%)
Figure 24.3Global Microbiome Therapeutics Market Share, By Regulatory Pathway (%)
Figure 25.3Global Microbiome Therapeutics Market Share, By End User (%)
Figure 26.3Global Microbiome Therapeutics Market Share, By Distribution Channel (%)
Figure 28.2Share, By Geography, 2020–2034 (%)
Figure 28.3Share, By Geography Analysis, 2025, Market Share and CAGR
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Table 1.3Microbiome Therapeutics Comparison By Segments
Table 4.1.2Market Size Estimation
Table 15.1Global Microbiome Therapeutics Market Size — Total
Table 15.2Market Size, by Segment (By Product Type, By Indication, By Route of Administration, By Source of Microbiota, By Development Stage, By Therapeutic Area, By Dosage Form, By Patient Age Group, By Regulatory Pathway, By End User, By Distribution Channel)
Table 16.2Global Microbiome Therapeutics Market Size, By Product Type, 2020–2034, Revenue (USD Million)
Table 16.3.1.1Market Size, By Live Biotherapeutic Products (LBPs), 2020–2034, Revenue (USD Million)
Table 16.3.1.2Live Biotherapeutic Products (LBPs) Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 16.3.1.3Live Biotherapeutic Products (LBPs) Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 16.3.1.4Live Biotherapeutic Products (LBPs) Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 16.3.1.5Live Biotherapeutic Products (LBPs) Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 16.3.1.6Live Biotherapeutic Products (LBPs) Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 16.3.1.7Live Biotherapeutic Products (LBPs) Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 16.3.1.8Live Biotherapeutic Products (LBPs) Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 16.3.1.9Live Biotherapeutic Products (LBPs) Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 16.3.1.10Live Biotherapeutic Products (LBPs) Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 16.3.1.11Live Biotherapeutic Products (LBPs) Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 17.2Global Microbiome Therapeutics Market Size, By Indication, 2020–2034, Revenue (USD Million)
Table 17.3.1.1Market Size, By Clostridioides difficile Infection, 2020–2034, Revenue (USD Million)
Table 17.3.1.2Clostridioides difficile Infection Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 17.3.1.3Clostridioides difficile Infection Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 17.3.1.4Clostridioides difficile Infection Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 17.3.1.5Clostridioides difficile Infection Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 17.3.1.6Clostridioides difficile Infection Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 17.3.1.7Clostridioides difficile Infection Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 17.3.1.8Clostridioides difficile Infection Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 17.3.1.9Clostridioides difficile Infection Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 17.3.1.10Clostridioides difficile Infection Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 17.3.1.11Clostridioides difficile Infection Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 18.2Global Microbiome Therapeutics Market Size, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 18.3.1.1Market Size, By Oral, 2020–2034, Revenue (USD Million)
Table 18.3.1.2Oral Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 18.3.1.3Oral Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 18.3.1.4Oral Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 18.3.1.5Oral Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 18.3.1.6Oral Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 18.3.1.7Oral Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 18.3.1.8Oral Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 18.3.1.9Oral Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 18.3.1.10Oral Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 18.3.1.11Oral Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 19.2Global Microbiome Therapeutics Market Size, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 19.3.1.1Market Size, By Human Donor-Derived, 2020–2034, Revenue (USD Million)
Table 19.3.1.2Human Donor-Derived Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 19.3.1.3Human Donor-Derived Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 19.3.1.4Human Donor-Derived Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 19.3.1.5Human Donor-Derived Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 19.3.1.6Human Donor-Derived Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 19.3.1.7Human Donor-Derived Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 19.3.1.8Human Donor-Derived Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 19.3.1.9Human Donor-Derived Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 19.3.1.10Human Donor-Derived Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 19.3.1.11Human Donor-Derived Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 20.2Global Microbiome Therapeutics Market Size, By Development Stage, 2020–2034, Revenue (USD Million)
Table 20.3.1.1Market Size, By Approved and Marketed, 2020–2034, Revenue (USD Million)
Table 20.3.1.2Approved and Marketed Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 20.3.1.3Approved and Marketed Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 20.3.1.4Approved and Marketed Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 20.3.1.5Approved and Marketed Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 20.3.1.6Approved and Marketed Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 20.3.1.7Approved and Marketed Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 20.3.1.8Approved and Marketed Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 20.3.1.9Approved and Marketed Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 20.3.1.10Approved and Marketed Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 20.3.1.11Approved and Marketed Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 21.2Global Microbiome Therapeutics Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 21.3.1.1Market Size, By Gastroenterology, 2020–2034, Revenue (USD Million)
Table 21.3.1.2Gastroenterology Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 21.3.1.3Gastroenterology Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 21.3.1.4Gastroenterology Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 21.3.1.5Gastroenterology Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 21.3.1.6Gastroenterology Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 21.3.1.7Gastroenterology Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 21.3.1.8Gastroenterology Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 21.3.1.9Gastroenterology Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 21.3.1.10Gastroenterology Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 21.3.1.11Gastroenterology Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 22.2Global Microbiome Therapeutics Market Size, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 22.3.1.1Market Size, By Capsules, 2020–2034, Revenue (USD Million)
Table 22.3.1.2Capsules Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 22.3.1.3Capsules Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 22.3.1.4Capsules Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 22.3.1.5Capsules Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 22.3.1.6Capsules Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 22.3.1.7Capsules Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 22.3.1.8Capsules Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 22.3.1.9Capsules Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 22.3.1.10Capsules Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 22.3.1.11Capsules Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 23.2Global Microbiome Therapeutics Market Size, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 23.3.1.1Market Size, By Adults, 2020–2034, Revenue (USD Million)
Table 23.3.1.2Adults Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 23.3.1.3Adults Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 23.3.1.4Adults Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 23.3.1.5Adults Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 23.3.1.6Adults Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 23.3.1.7Adults Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 23.3.1.8Adults Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 23.3.1.9Adults Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 23.3.1.10Adults Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 23.3.1.11Adults Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 24.2Global Microbiome Therapeutics Market Size, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 24.3.1.1Market Size, By Biologic (BLA/Drug) Pathway, 2020–2034, Revenue (USD Million)
Table 24.3.1.2Biologic (BLA/Drug) Pathway Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 24.3.1.3Biologic (BLA/Drug) Pathway Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 24.3.1.4Biologic (BLA/Drug) Pathway Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 24.3.1.5Biologic (BLA/Drug) Pathway Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 24.3.1.6Biologic (BLA/Drug) Pathway Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 24.3.1.7Biologic (BLA/Drug) Pathway Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 24.3.1.8Biologic (BLA/Drug) Pathway Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 24.3.1.9Biologic (BLA/Drug) Pathway Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 24.3.1.10Biologic (BLA/Drug) Pathway Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 24.3.1.11Biologic (BLA/Drug) Pathway Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 25.2Global Microbiome Therapeutics Market Size, By End User, 2020–2034, Revenue (USD Million)
Table 25.3.1.1Market Size, By Hospitals, 2020–2034, Revenue (USD Million)
Table 25.3.1.2Hospitals Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 25.3.1.3Hospitals Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 25.3.1.4Hospitals Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 25.3.1.5Hospitals Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 25.3.1.6Hospitals Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 25.3.1.7Hospitals Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 25.3.1.8Hospitals Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 25.3.1.9Hospitals Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 25.3.1.10Hospitals Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 25.3.1.11Hospitals Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 26.2Global Microbiome Therapeutics Market Size, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 26.3.1.1Market Size, By Hospital Pharmacies, 2020–2034, Revenue (USD Million)
Table 26.3.1.2Hospital Pharmacies Size and Projections, By Product Type, 2020–2034, Revenue (USD Million)
Table 26.3.1.3Hospital Pharmacies Size and Projections, By Indication, 2020–2034, Revenue (USD Million)
Table 26.3.1.4Hospital Pharmacies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 26.3.1.5Hospital Pharmacies Size and Projections, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 26.3.1.6Hospital Pharmacies Size and Projections, By Development Stage, 2020–2034, Revenue (USD Million)
Table 26.3.1.7Hospital Pharmacies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 26.3.1.8Hospital Pharmacies Size and Projections, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 26.3.1.9Hospital Pharmacies Size and Projections, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 26.3.1.10Hospital Pharmacies Size and Projections, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 26.3.1.11Hospital Pharmacies Size and Projections, By End User, 2020–2034, Revenue (USD Million)
Table 28.1Revenue, By Geography, 2020–2034, Revenue (USD Million)
Table 28.4Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 29.1Overview, 2020–2034
Table 29.2Size and Projections, 2020–2034, Revenue (USD Million)
Table 29.2.1By Product Type, 2020–2034
Table 29.2.2By Indication, 2020–2034
Table 29.2.3By Route of Administration, 2020–2034
Table 29.2.4By Source of Microbiota, 2020–2034
Table 29.2.5By Development Stage, 2020–2034
Table 29.2.6By Therapeutic Area, 2020–2034
Table 29.2.7By Dosage Form, 2020–2034
Table 29.2.8By Patient Age Group, 2020–2034
Table 29.2.9By Regulatory Pathway, 2020–2034
Table 29.2.10By End User, 2020–2034
Table 29.2.11By Distribution Channel, 2020–2034
Table 29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 29.3.1.4US — Market Overview, 2020–2034, Revenue (USD Million)
Table 29.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Million)
Table 29.3.1.6US Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Table 29.3.1.7US Market Overview, By Indication, 2020–2034, Revenue (USD Million)
Table 29.3.1.8US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 29.3.1.9US Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 29.3.1.10US Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
Table 29.3.1.11US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 29.3.1.12US Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 29.3.1.13US Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 29.3.1.14US Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 29.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Million)
Table 29.3.1.16US Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 30.1Overview, 2020–2034
Table 30.2Size and Projections, 2020–2034, Revenue (USD Million)
Table 30.2.1By Product Type, 2020–2034
Table 30.2.2By Indication, 2020–2034
Table 30.2.3By Route of Administration, 2020–2034
Table 30.2.4By Source of Microbiota, 2020–2034
Table 30.2.5By Development Stage, 2020–2034
Table 30.2.6By Therapeutic Area, 2020–2034
Table 30.2.7By Dosage Form, 2020–2034
Table 30.2.8By Patient Age Group, 2020–2034
Table 30.2.9By Regulatory Pathway, 2020–2034
Table 30.2.10By End User, 2020–2034
Table 30.2.11By Distribution Channel, 2020–2034
Table 30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 30.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Million)
Table 30.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Million)
Table 30.3.1.6Germany Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Table 30.3.1.7Germany Market Overview, By Indication, 2020–2034, Revenue (USD Million)
Table 30.3.1.8Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 30.3.1.9Germany Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 30.3.1.10Germany Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
Table 30.3.1.11Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 30.3.1.12Germany Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 30.3.1.13Germany Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 30.3.1.14Germany Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 30.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Million)
Table 30.3.1.16Germany Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 31.1Overview, 2020–2034
Table 31.2Size and Projections, 2020–2034, Revenue (USD Million)
Table 31.2.1By Product Type, 2020–2034
Table 31.2.2By Indication, 2020–2034
Table 31.2.3By Route of Administration, 2020–2034
Table 31.2.4By Source of Microbiota, 2020–2034
Table 31.2.5By Development Stage, 2020–2034
Table 31.2.6By Therapeutic Area, 2020–2034
Table 31.2.7By Dosage Form, 2020–2034
Table 31.2.8By Patient Age Group, 2020–2034
Table 31.2.9By Regulatory Pathway, 2020–2034
Table 31.2.10By End User, 2020–2034
Table 31.2.11By Distribution Channel, 2020–2034
Table 31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 31.3.1.4India — Market Overview, 2020–2034, Revenue (USD Million)
Table 31.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Million)
Table 31.3.1.6India Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Table 31.3.1.7India Market Overview, By Indication, 2020–2034, Revenue (USD Million)
Table 31.3.1.8India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 31.3.1.9India Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 31.3.1.10India Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
Table 31.3.1.11India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 31.3.1.12India Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 31.3.1.13India Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 31.3.1.14India Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 31.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Million)
Table 31.3.1.16India Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 32.1Overview, 2020–2034
Table 32.2Size and Projections, 2020–2034, Revenue (USD Million)
Table 32.2.1By Product Type, 2020–2034
Table 32.2.2By Indication, 2020–2034
Table 32.2.3By Route of Administration, 2020–2034
Table 32.2.4By Source of Microbiota, 2020–2034
Table 32.2.5By Development Stage, 2020–2034
Table 32.2.6By Therapeutic Area, 2020–2034
Table 32.2.7By Dosage Form, 2020–2034
Table 32.2.8By Patient Age Group, 2020–2034
Table 32.2.9By Regulatory Pathway, 2020–2034
Table 32.2.10By End User, 2020–2034
Table 32.2.11By Distribution Channel, 2020–2034
Table 32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 32.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Million)
Table 32.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Million)
Table 32.3.1.6Brazil Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Table 32.3.1.7Brazil Market Overview, By Indication, 2020–2034, Revenue (USD Million)
Table 32.3.1.8Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 32.3.1.9Brazil Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 32.3.1.10Brazil Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
Table 32.3.1.11Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 32.3.1.12Brazil Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 32.3.1.13Brazil Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 32.3.1.14Brazil Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 32.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Million)
Table 32.3.1.16Brazil Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
Table 33.1Overview, 2020–2034
Table 33.2Size and Projections, 2020–2034, Revenue (USD Million)
Table 33.2.1By Product Type, 2020–2034
Table 33.2.2By Indication, 2020–2034
Table 33.2.3By Route of Administration, 2020–2034
Table 33.2.4By Source of Microbiota, 2020–2034
Table 33.2.5By Development Stage, 2020–2034
Table 33.2.6By Therapeutic Area, 2020–2034
Table 33.2.7By Dosage Form, 2020–2034
Table 33.2.8By Patient Age Group, 2020–2034
Table 33.2.9By Regulatory Pathway, 2020–2034
Table 33.2.10By End User, 2020–2034
Table 33.2.11By Distribution Channel, 2020–2034
Table 33.3Size and Projections, By Countries, 2020–2034, Revenue (USD Million)
Table 33.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Million)
Table 33.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Million)
Table 33.3.1.6GCC Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Table 33.3.1.7GCC Market Overview, By Indication, 2020–2034, Revenue (USD Million)
Table 33.3.1.8GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Table 33.3.1.9GCC Market Overview, By Source of Microbiota, 2020–2034, Revenue (USD Million)
Table 33.3.1.10GCC Market Overview, By Development Stage, 2020–2034, Revenue (USD Million)
Table 33.3.1.11GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Million)
Table 33.3.1.12GCC Market Overview, By Dosage Form, 2020–2034, Revenue (USD Million)
Table 33.3.1.13GCC Market Overview, By Patient Age Group, 2020–2034, Revenue (USD Million)
Table 33.3.1.14GCC Market Overview, By Regulatory Pathway, 2020–2034, Revenue (USD Million)
Table 33.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Million)
Table 33.3.1.16GCC Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Million)
Scope
Questions This Report Answers
6 questions01
What is the market size and growth rate, globally and by region?
02
How is the market segmented, and which segments lead?
03
Which regions and countries are covered, and how do they compare?
04
What are the key drivers, restraints, opportunities and challenges?
05
Who are the leading companies operating in this market?
06
What trends are expected to shape the market through the forecast period?
Questions
Frequently Asked Questions
01What is the Microbiome Therapeutics Market projected to reach?
USD 1690 USD Million by 2034, CAGR 22.42%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 53% of global revenue through 2034.
05Which segment leads the market?
Live Biotherapeutic Products (LBPs) is the largest line by product type, at 38% of revenue in 2025.
06Who are the key companies profiled?
Ferring Pharmaceuticals, Seres Therapeutics, Inc., Nestlé Health Science, Vedanta Biosciences, Inc., MaaT Pharma SA, Finch Therapeutics Group, Inc., Microbiotica Ltd, Destiny Pharma plc, 4D Pharma plc, Evelo Biosciences, Inc., Kaleido Biosciences, Inc., AOBiome Therapeutics, Inc., Osel, Inc., Rebiotix Inc., Assembly Biosciences, Inc., Enterome SA, Genome & Company, Siolta Therapeutics, Inc., Exeliom Biosciences, NuBiyota, Biomica Ltd, Servatus Ltd, Taisho Pharmaceutical Co., Ltd., Sanofi S.A., Danone S.A., Sun Pharmaceutical Industries Ltd., Genetic Analysis AS, Federation Bio. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
425+
Dedicated research analysts
1,200+
Reports published
Why CDI
Why choose CDI
Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
Explore
Related Reports
Pharmaceuticals & Biotech
Ragweed Pollen Allergy Treatment Market
USD 4.14 Bn by 2034, CAGR 8.99%
Pharmaceuticals & Biotech
Complement Inhibitors Market
USD 31.85 Bn by 2034, CAGR 10.77%
Pharmaceuticals & Biotech
Clinical Trial Supplies Market
USD 10.3 Bn by 2034, CAGR 8.3%
Pharmaceuticals & Biotech
Biologics API Market
USD 138.6 Bn by 2034, CAGR 7.8%
Pharmaceuticals & Biotech
Abilify Maintena Market
USD 2.64 Bn by 2034, CAGR 7.5%
Pharmaceuticals & Biotech
Hereditary Angioedema
USD 7.15 Bn by 2034, CAGR 7.27%